Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Beyond weight loss: protecting muscle with GLP-1s. Dr Almandoz shares strategies to preserve muscle, optimize body composition, and enhance health outcomes during GLP-1 therapy.

While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...

“The rapid evolution of the pharmaceutical industry, particularly in the growing weight loss and diabetes and obesity treatment market, underscores the critical role of innovation and the need ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...